Phalguni Deswal

OncoX will pay an upfront cost of $12.5m in cash and shares for rights to ABVC’s non-small cell lung cancer therapy, BLEX 404.

NanoString had filed for Chapter 11 bankruptcy after losing the $31m patent infringement case against 10X Genomics.

Roche’s Alecensa is now approved as an adjuvant therapy for patients with ALK-positive non-small cell lung cancer (NSCLC).

Chiesi also purchased carbon credits to compensate for the emissions for its entire UK portfolio of respiratory medicines. Share this article Copy Link

Novartis and MMV's Coartem formulation for infants weighing 5kg met the primary endpoint in Phase II/III trial of infants and neonates with malaria.

Lutathera is approved by the US FDA to treat patients aged 12 years and older with rare gastroenteropancreatic neuroendocrine cancer.

Deepull plans to seek partnerships and start clinical trials for the UIICORE system next year.

Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.

The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.

Dynamic's U-Rhythm device captures hormone data over 24 hours and can help diagnose and monitor hormone-related disorders.